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Abstract
Background: Prostacyclin receptor (IP) and thromboxane A2 receptor (TP) belong to rhodopsin-
type G protein-coupling receptors and respectively bind to prostacyclin and thromboxane A2
derived from arachidonic acid. Recently, we have determined the extracellular loop (eLP)
structures of the human TP receptor by 2-D 1H NMR spectroscopy using constrained peptides
mimicking the individual eLP segments. The studies have identified the segment along with several
residues in the eLP domains important to ligand recognition, as well as proposed a ligand
recognition pocket for the TP receptor.
Results: The IP receptor shares a similar primary structure in the eLPs with those of the TP
receptor. Forty percent residues in the second eLPs of the receptors are identical, which is the
major region involved in forming the ligand recognition pocket in the TP receptor. Based on the
high homology score, the eLP domains of the IP receptor were constructed by the homology
modeling approach using the NMR structures of the TP eLPs as templates, and then configured to
the seven transmembrane (TM) domains model constructed using the crystal structure of the
bovine rhodopsin as a template. A NMR structure of iloprost was docked into the modeled IP
ligand recognition pocket. After dynamic studies, the segments and residues involved in the IP
ligand recognition were proposed. A key residue, Arg173 involved in the ligand recognition for the
IP receptor, as predicted from the modeling, was confirmed by site-directed mutagenesis.
Conclusion: A 3-D model of the human IP receptor was constructed by homology modeling using
the crystal structure of bovine rhodopsin TM domains and the NMR structures of the synthetic
constrained peptides of the eLP domains of the TP receptor as templates. This strategy can be
applied to molecular modeling and the prediction of ligand recognition pockets for other
prostanoid receptors.
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Background
Prostanoids including thromboxane A2 (TXA2) and pros-
taglandins D2 (PGD2), E2 (PGE2), F2 (PGF2) and I2 (PGI2)
act as local hormones in the vicinity of their production
sites to regulate hemostasis and smooth muscle functions,
which are mediated by specific prostanoid receptors in the
plasma membrane. The receptors are classified into five
basic types based on their cognate prostanoid (PGD2,
PGE2, PGF2α, PGI2 or TXA2) and are termed DP, EP, FP, IP
and TP receptors, respectively [1]. In addition, the EP
receptors are subdivided into four subtypes (EP1, EP2,
EP3 and EP4) based on their different signaling responses
to PGE2. Human TP was first purified from a platelet in
1989 and its cDNA was cloned from placenta in 1991
[2,3]. Other prostanoid receptor cDNAs, including those
for DP, EP1, EP2, EP3, EP4, FP and IP have also been
cloned, and their primary biologic functions have been
identified.
Prostanoid receptors can be divided into two functional
groups using smooth muscle assays: relaxant receptors
(including DP, EP2, EP4, and IP) and excitatory receptors
(including EP1, FP, and TP). All known prostanoid recep-
tors belong to the rhodopsin-type G protein-coupled
receptor (GPCR) super-family, which has seven conserved
TM domains. The diverse and/or opposite biological func-
tions of the individual prostanoid receptors involve selec-
tive ligand binding on their extracellular and/or TM
domains and the interaction with different heterotrimeric
G proteins on their intracellular domains [1].
For over a decade, structural and functional studies of
prostanoid receptors have focused on the identification of
the specific sites for ligand binding and G protein cou-
pling. The homology alignment-based mutagenesis stud-
ies of the receptor TM domains have suggested that the
conserved regions in the third and seventh TM domains
are involved in binding the core structures of the prosta-
noids, which consist of a carboxylic acid, a hydroxyl group
on carbon 15 and two aliphatic side chains [4-6]. How-
ever, the TM domains belong to the conserved regions in
all known prostanoid receptors, and therefore, probably
do not define the differences among the receptors in spe-
cific interactions with their ligands. Current focus has
been directed toward the involvement of the extracellular
loops (eLPs) of prostanoid receptors in the selective lig-
and recognition, similar to some other GPCRs [7-15].
However, interpretation of the eLP specific determinants
response to the specific ligand binding among prostanoid
receptors is limited by the lack of experimental 3-D struc-
tural information for the extramembrane domains. Struc-
tural characterization of both the extracellular and
intracellular domains of the prostanoid receptors needed
to elucidate the molecular mechanisms of specific ligand
recognitions and G protein couplings remains a major
challenge.
Molecular modeling has been widely used to create a
working model of the GPCR using a known x-ray crystal
structure of rhodopsin. Electron diffraction and electron
microscopy studies have succeeded in determining the
structure of the GPCR-like protein, bacteriorhodopsin
(BR), at low and medium resolution [16,17]. The high-
resolution 3-D structure of BR has also been determined
by X-ray crystal studies [18,19]. Using the BR structure as
a template, a number of working models of the conserved
TM domains for the rhodopsin-type GPCRs have been
constructed by homology modeling [6,20-32]. Most of
these models assumed that the GPCRs had the same spa-
tial arrangement for the seven helices as BR. However, it
has recently been suggested that BR is not a suitable tem-
plate for the construction of GPCR TM models because BR
does not function as a GPCR and there is no overall signif-
icant sequence similarity between BR and the GPCRs [33].
Further evidence is given from the structural maps of
bovine, frog and squid rhodopsins [34-39], which indi-
cate that the arrangement of the helices in the rhodopsins
is indeed different from that in BR. As such, it is believed
that the crystal structure of the TM domains of bovine rho-
dopsin (bRH) is a more suitable template for constructing
working models of mammalian GPCR TM domains,
which include the prostanoid receptors.
It is almost impossible to build the structural extra- and
intra-cellular loop models for the prostanoid receptors
using the corresponding structures of BR or bRH due to a
number of differences, including size and sequence varia-
tion. However, understanding the structural features of
the extracellular loops of the prostanoid receptors is the
key step toward uncovering the ligand binding selectivity.
To overcome the difficulty recently, we have successfully
determined the solution structures of the individual eLP
domains for the human TP receptor, and identified that its
ligand (antagonist) recognition pocket is mainly formed
by the second eLP (eLP2) and the disulfide bond between
the eLP2 and the first eLP (eLP1). This was done using
newly-developed concepts including, computation-
guided constrained peptide synthesis and NMR experi-
ment-guided mutagenesis approaches. These results offer
a basis for understanding the ligand recognition sites for
the other prostanoid receptors through the homology
modeling approach using the NMR structures of the eLP
segments, which share many similarities with the other
prostanoid receptors, especially the IP receptor. In this
paper, we describe the approaches used to construct the
working model for the IP receptor by homology modeling
using x-ray TM structures of bRH and NMR structures of
the eLPs of the TP receptor as templates. We also discuss
its value in predicting the residues involved in ligand rec-BMC Biochemistry 2005, 6:23 http://www.biomedcentral.com/1471-2091/6/23
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ognition for the IP receptor through modeling and muta-
genesis.
Results
Homology modeling for the seven TM domains of the 
human IP and TP receptors using the crystal structure of 
the TM domains of the BR as a template
The amino acid sequences of the human IP and TP recep-
tors and bRH were downloaded from Gene Bank. The first
step is to highlight the multiple sequence alignments
between the TM domains of bRH, TP, and IP receptors.
The putative TM domains of the IP and TP receptors are
based on the hydropathy analysis described in the original
cloning papers [3,40]. The significant similarities (data
not shown) in the TM domains reflect the similarity of the
general backbone structures between the TP and IP recep-
tors with bRH. To construct the homology models of the
TM domains of the IP and TP receptors, the crystal struc-
tures of the TM domains of bRH were used as a template,
and its backbone conformations were adopted for the
each TM domains of the IP and TP receptors using the
Insight II package on a SGI Octane workstation. The well-
developed commercial software, Insight II, has been
widely used in various academic fields for protein mode-
ling. The detailed steps have been described previously
[41,42]. The backbone structural model of the TM
domains of the IP (Figure 1) and TP (data not shown)
were obtained. It shall be indicated that the gaps between
the template and objects were fixed by the molecular
annealing computation.
Structural features of the reported 3-D NMR structures of 
the eLPs of the TP receptor
Synthetic peptides corresponding to the eLP domains of
the human TP receptor were mimicked by a constrained
peptide technique with the N- and C-termini connected
by a homocysteine disulfide bond [43,44]. The con-
strained eLP2 peptide was likely able to adopt an active
conformation, which was evidenced by the binding of the
peptide to the receptor ligand using fluorescence and CD
spectroscopic studies [43-45]. Recently, by way of 2-D 1H
Sequence alignment of the eLPs between the human IP and  TP receptors Figure 2
Sequence alignment of the eLPs between the human IP and 
TP receptors. The sequences of the putative eLP domains of 
the human IP (45) and TP (3) receptors were aligned by a 
sequence alignment program in Insight II software package 
and manual adjustment. The identical and highly similar resi-
dues between the TP and IP are shaded. The residues in the 
eLP2 regions previously identified important to the ligand 
binding for the TP receptor (10) and their corresponding 
residues in the IP receptor are underlined.
                      88                                            106 
TP eLP1:  QHAALFEWHAVD-PGCRLCR 
         77                   94 
IP eLP1:  RNSSLLGL-ARGGPA--LCDA
                      173                                                  193 
TP eLP2: RYTVQY-PGSWCFLTLGAESGD
         159                     181
IP eLP2: GQHQQYCPGSWCFLRMRWAQPGG
           273               289 
TP eLP3:  PPAMSPAGQLSRTTEKE
           261                270
IP eLP3: TQA-V-APD-SSS-EMGD
Homology modeling of the seven TM domains of human IP  receptor Figure 1
Homology modeling of the seven TM domains of human IP 
receptor. 3-D backbone structure of the seven TM domains 
of the human TP receptor were created by homology mode-
ling using the crystal structural backbones of the TM domains 
of the bovine rhodopsin as templates.
12Å
12Å 10 Å
Intracellular Side
Extracellular Side
7 TMsBMC Biochemistry 2005, 6:23 http://www.biomedcentral.com/1471-2091/6/23
Page 4 of 11
(page number not for citation purposes)
NMR experiments, complete 1H NMR assignments for the
2-D spectra including, nuclear Overhauser effect correla-
tion spectroscopy (NOESY), total correlation spectros-
copy (TOCSY), double-quantum-filtered correlation
spectroscopy (DQF-COSY), and structural construction
were used to determine the overall 3-D structures of the
constrained peptides mimicking the three TP eLPs (eLP1,
[43], eLP2 [44] and eLP3 [45]). All of the NMR structures
indicate the presence of β-turns in the loops [43]. The dis-
tance between the N- and C-termini of the peptides
shown in the NMR structures was 10–14.2 Å, which
matched the distance between the two TM helices con-
necting the eLPs in the TM domain model of the TP recep-
tor. These structural features allowed the NMR structures
of the constrained TP eLP peptides to be grafted onto the
region of the TP receptor model in a configuration with-
out further modifications [43,45]. This study suggests that
the approach using the constrained loop peptide greatly
increases the likelihood of characterization of the struc-
tural features of the extracellular domains of the TP recep-
tor. It offers a structural template to model the
extracellular domains of other prostanoid receptors,
which as of yet have no defined crystallographic struc-
tures. The IP receptor is one example which shares signif-
icant similarities in its extracellular domains with those of
the TP receptors.
Sequence alignment of the three eLPs between the human 
IP and TP receptors
Sequence analysis has indicated that the amino acid resi-
dues in the eLP domains are not conserved between bRH
and prostanoid receptors, such as the IP receptor. This has
limited the use of the crystal structure of the eLP domains
of bRH for homology modeling of the prostanoid recep-
tors. Thus, the experimental NMR eLP structures of the TP
receptor become useful in constructing a model of the IP
receptor because they are conserved in the eLP domains.
The eLP domains of the IP and TP receptors were identi-
fied from the hydropathy analysis described by the origi-
nal cloning papers [3,40]. The three eLPs between the TP
and IP were aligned and are shown in the Figure 2. The
lengths of the three IP eLP domains are similar to those of
the TP receptor, which allows them to align with no major
gaps. The Cys residues (Cys105 in the eLP1 and Cys183 in
the eLP2) of the TP receptor that form a disulfide bond
[43], thereby controlling the conformation of the eLPs,
are conserved in the IP receptor (Figure 2). Among the
three eLPs, the most conserved region is localized in the
eLP2 (40% identity, Figure 2), which has been identified
to play a major structural role in forming the ligand recog-
nition site for the TP receptor [10]. In addition, there are
33% and 36% of the sequence homologies for the eLP1
and eLP3, respectively (Figure 2). Thus, using the NMR
structures of the TP eLPs as a template for modeling the IP
eLPs will be useful in rationalizing the structural and func-
Configuration of the modeled 3-D backbone structures of  the three IP eLP domains (Figure 4) onto the working model  of the seven TM domains of the IP receptor Figure 4
Configuration of the modeled 3-D backbone structures of 
the three IP eLP domains (Figure 4) onto the working model 
of the seven TM domains of the IP receptor. Before (A) and 
after (B) the connections of the eLP structures to the seven 
TMs through chemical bonds are displayed for their compar-
ison.
The predicted backbone structures of the three eLP domains  of the human IP receptor Figure 3
The predicted backbone structures of the three eLP domains 
of the human IP receptor. The 3-D structural models of the 
eLPs were constructed by homology modeling with the NMR 
structures of the eLP2 (48), the eLP3 (49) and the eLP1 
(unpublished data) of the human TP receptor as templates 
using the molecular modeling package of Insight II and Dis-
cover software packages. The conformation of the eLP2 is 
placed in a position with respect to the formation of a 
disulfide bond between the Cys92 in the eLP1 and Cys170 in 
the eLP2.
Cys92
Cys170
eLP2 eLP1
eLP3BMC Biochemistry 2005, 6:23 http://www.biomedcentral.com/1471-2091/6/23
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tional features of the eLPs in the IP receptor. The individ-
ual similarities of the alignment are listed in the Figure 2.
Homology modeling for the eLP domains of human IP 
receptor
The backbone structures of the individual IP eLPs were
constructed by homology modeling using the NMR struc-
tures of the TP eLPs as templates with respect to the
disulfide bond formation between Cys92 in the eLP1 and
Cys170 in the eLP2 of the IP receptor (Figure 3). After
energy minimization, each eLP structure was configured
to the TM domain model. Each configuration was made
based on the three following considerations: 1) placing
the N- and C-termini of the eLP1, eLP2 and eLP3 to the C-
and N-termini of the TM2 and TM3, TM4 and TM5, and
TM6 and TM7; 2) matching the distances of the N- and C-
termini of the eLPs with the corresponding distance
between those of the TM helix (Figure 4A), 3) connecting
the eLPs to the TMs through chemical bonds by Insight II
calculation using Discover program (Figure 4B), and 4)
forming a disulfide bond between Cys92, at the end of the
eLP1, and Cys170, in the center position of the eLP2 (Fig-
ure 4B). After completing the configuration, 500 steps of
energy minimization were used to refine the conforma-
tion of the model eLPs. As shown in Figure 4B, the con-
structed eLPs could be fitted into the conserved TM
domains with respect to the cysteine disulfide bond
between eLP1 and eLP2, without major violations in the
structural calculation or significantly altering the original
backbone structures in the original conformations before
the connection (Figure 4A). Dynamic studies for the par-
Analysis for the mutation of Arg173 to Ala residue of the  recombinant human IP receptor Figure 6
Analysis for the mutation of Arg173 to Ala residue of the 
recombinant human IP receptor. A). Western blot analysis. 
Fifty micrograms of COS-7 cells transfected with wild-type 
(WT) or a mutant IP receptor (R173A) cDNA was subjected 
to SDS-PAGE and transferred onto a nitrocellulose mem-
brane. The membrane was probed with rabbit anti-IP peptide 
antibody. (B) The ligand binding activities of wild-type and 
mutant TP receptor. 300 µg of the protein prepared from 
the COS-7 cells transfected with cDNA of the wild-type 
(WT) or the R173A mutant was incubated with 4 nM [3H]-
iloprost (30,000 cpm) in the absence or presence of unla-
beled iloprost (1 µM) in a reaction volume of 100 µl. After 1 
h incubation, the reaction was stopped and the binding activ-
ity of the recombinant IP receptor was measured as 
described in the methods. The binding activity of wild-type 
receptor was considered as 100% (2,000 cpm).
Ligand docking with the eLP domains of the IP receptor Figure 5
Ligand docking with the eLP domains of the IP receptor. The 
four residues including Gln162, Leu172, Arg173 and Met174 
in the IP eLP2 (eLP1, bleu color; eLP2, red color and eLP3, 
yellow color) in contact with iloprost were predicted by the 
sequence alignment (Figure 1) using the identified four resi-
dues (Val176, Leu185, Thr186 and Leu187) in the TP eLP2 
contacted with SQ29,548 (10) as a template. 3-D NMR 
structure of the IP receptor agonist, iloprost (42) was 
docked into the putative ligand recognition pocket formed by 
the three eLPs with respect to the contacts with Leu172, 
Arg1173 and Met174 in the opening of the pocket. In addi-
tion, the two residues, Ala177 and Gln178 involved in con-
tacts with iloprost predicted by NMR spectroscopic studies 
(42) were also used as constraints for the iloprost docking to 
the recognition pocket. The configuration of the model was 
minimized using 1,000-step energy minimization after the ilo-
prost was docked into the pocket. The TM domains of the IP 
receptor are showed with green colors.BMC Biochemistry 2005, 6:23 http://www.biomedcentral.com/1471-2091/6/23
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ent NMR structures of the TP eLPs have been described in
our recent publication [43], in which 20 structural confor-
mations have been generated and used to evaluate the
loop folding. Limited conformational changes (rmsd =
1.2 Å) were observed [43]. The modeled structures of the
IP eLPs described above adopted a similar variation of the
conformations (data not shown). This information indi-
cated that the folding of the IP eLPs is in a reasonable con-
formation.
Ligand docking in the IP receptor model
To understand ligand selectivity and the action mecha-
nisms of the IP receptor, it is very important to identify its
specific ligand recognition/binding site. The IP receptor
was cloned a decade ago, many attempts have been made
to localize the segments and residues important to its lig-
and binding activities. However, little structural informa-
tion is available. Through molecular modeling, we have
made attempts to solve this problem.
The IP receptor ligand, prostacyclin, is not stable in solu-
tion and does not have 3D structural information.
Recently, we have determined the solution structure of a
stable IP receptor agonist, iloprost, using NMR spectros-
copy [42]. It offers an experimental structure for molecu-
lar docking between the ligand and the IP receptor. On the
other hand, based on the NMR experimental and muta-
genesis results obtained for the TP receptor, the four resi-
dues (Val176, Leu185, Thr186 and Leu187) identified as
being involved in ligand recognition are mainly localized
in the eLP2 region [43]. The results indicated that perhaps
the corresponding residues in the conserved IP eLP2
region are also likely to be involved in ligand recognition.
This hypothesis has been supported by our recent NMR
spectroscopic studies using a synthetic eLP2 fragment [42].
This information provided the basis for our study of the
interaction between the IP receptor and its ligand using a
molecular docking approach. The NMR structure of ilo-
prost was docked into the pocket of the IP model corre-
sponding to the ligand recognition pocket of the TP
receptor as identified by NMR and mutagenesis studies
[10] using Insight II and Discover computation proce-
dures. The residues crucial to the TP ligand recognition
[10] were used as a basis for localizing the possible resi-
dues involved in ligand contact in the IP receptor model
(Figure 5). The orientation of the iloprost structure was
positioned in contact with the side chains of the three of
the four residues (Gln162, Leu172, Arg173 and Meth174,
Figure 2 and 5) in the IP eLP2, corresponding to the pre-
viously identified contact sites among the residues of the
TP eLP2 at Val176, Leu185, Thr186 and Leu187 with
SQ29,548 (a TP receptor ligand) (10). In addition, it has
been found that the residues Ala177 and Gln178 in the IP
eLP2 fragment could interact with iloprost by our NMR
spectroscopic studies [42]. It has also been taken for the
consideration of the iloprost docking with the IP receptor
Kinetic properties of [3H] iloprost binding to the recom- binant IP receptors expressed in COS-7 cells Figure 8
Kinetic properties of [3H] iloprost binding to the recom-
binant IP receptors expressed in COS-7 cells. The cell mem-
brane protein prepared from COS-7 cells that transiently 
expressed the wild-type (squares), R173A mutant (circles) or 
R173T mutant (triangles) of the IP receptor was incubated 
with the increasing concentration of the [3H] iloprost.
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Analysis of the mutation of Arg173 to Thr residue and  Ser168 to Thr residue of the recombinant IP receptors Figure 7
Analysis of the mutation of Arg173 to Thr residue and 
Ser168 to Thr residue of the recombinant IP receptors. A). 
Western blot. B). Ligand binding activity. The methods are 
described in the Figure 6.BMC Biochemistry 2005, 6:23 http://www.biomedcentral.com/1471-2091/6/23
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(Figure 5). The structural complex of iloprost and the IP
receptor was then subjected to energy minimization to
find the best-fitting position of the iloprost conformation
in the proposed ligand recognition site of the receptor
(Figure 5). During the minimization, the main changes of
the structures were the side chains of the loops, but no sig-
nificant structural alternation for iloprost and the loop
backbones were observed.
Recently, we have published the structural information of
the ligand recognition site of TP receptor [43]. The
disulfide bond involved in forming the ligand recognition
pocket in the TP receptor has been confirmed by the
reducing of the disulfide bond in the presence and
absence of the ligand binds and the Cys mutations [43].
From this IP receptor model, we have also learned that the
disulfide bond between the eLP1 and eLP2 is involved in
forming the ligand recognition pocket (Figure 5). Reduc-
tion of the disulfide bond will alter the active conforma-
tion of the pocket of the receptor.
Confirmation of the NMR experiment-based modeling for 
prediction of the residues involved in IP receptor ligand 
recognition using recombinant IP receptor
Distinct characteristics are noted among the four pre-
dicted residues important to ligand recognition for the IP
receptor. Leu172 is both conserved between IP and TP
receptors. Gln162 does not lie within close proximity of
the opening of the pocket (Figure 5), and the side chain of
Met174 is likely not centered enough to make contact
with the ligand (Figure 5). Thus in looking at the model,
Arg173 becomes the residue with the highest potential for
the specific iloprost recognition (Figure 5). Based on this
hypothesis, the residue, Arg173, was subjected to muta-
genesis studies. First, the Arg residue in the IP eLP2 was
replaced with Ala to eliminate the charged side chain.
After transfection of the mutated IP receptor cDNA into
COS-7 cells, a similar expression level of the mutant and
wild type IP receptors was confirmed by Western blot (Fig-
ure 6A). The binding of the recombinant receptor to its
ligand was then performed using [3H]-iloprost and unla-
beled (cold) iloprost was used as a competitive ligand
(Figure 6B). The mutant with the single replacement of
the Arg residue with Ala lost its binding activity to the
receptor agonist as compared with the wild type (Figure
6B). These data indicate that the Arg residue, as predicted
from the IP model, is indeed important in ligand recogni-
tion. The results also confirm that the model is indeed
useful in providing information for structure and function
relationship studies of the IP receptor.
To further identify the specificity of the Arg residue in the
IP receptor, the Arg173 was then mutated to Thr that lies
in the corresponding position of the TP receptor (Figure
1). After expression of the mutant in COS-7 cells, con-
firmed by Western blot (Figure 7A) as described above,
the binding of the mutated IP receptor to iloprost was
tested. The Arg173Thr mutant retained about 40% ligand
binding activity as compared with the wild type IP recep-
tor (Figure 7B). In contrast, the control mutant of the IP
receptor, Ser168Thr, which is highly conserved in the all
of the prostanoid receptors, retained full activity binding
to iloprost (Figure 7B). The impairment of the Arg173
mutants binding to iloprost was further concluded by
kinetic studies as shown in Figure 8. These results indicate
that Arg173 is specifically important for ligand recogni-
tion in the IP receptor. The Arg residue in the IP and Thr
residue in the TP may be involved in the determination of
their ligand selectivities. If so, this will provide important
clues for further characterizing ligand selectivity of other
prostanoid receptors using the modeling and mutagenesis
approaches.
Discussion
The lack of the 3-D structural models of the prostanoid
receptors has become a major obstacle in both further
understanding their molecular mechanisms and in the
design of pharmacological intervention strategies. Thus,
developing useful approaches for further structural and
functional characterization of the GPCRs is crucial. The
crystal structure of rhodopsin offers a structural template
for the conserved TM helices of other GPCRs, including
the prostanoid receptors. The TM domain modeling for
the IP and TP receptors, using the x-ray structures of the
TM domains of bRH described in the paper is also suitable
for the modeling of the TM domains of other prostanoid
receptors. However, as described above, the bRH crystal
structure provides few structural and functional clues for
the extracellular and intracellular domains of the prosta-
noid receptors. One useful way to characterize the GPCR
functions is to assemble information obtained from stud-
ies using receptor fragments. Synthetic peptides have been
used as important tools in mimicking the functional
domains of GPCRs. Peptides corresponding to the C-ter-
minal extramembrane domains of the angiotensin II
AT1A receptor [46], natriuretic peptide receptor C [47],
testicular follicle stimulating hormone receptor [48] and
BR [49,50] have functional activities, which indicate that
these peptides can adopt similar structures in the cognate
parts of the intact receptors. The synthetic peptides corre-
sponding to the intracellular domains of the M4 subtype
muscarinic, cholinergic and α 2-adrenergic receptors
could directly bind to and activate their specific G proteins
[51]. Also, Yeagle et al have used the NMR structures of the
synthetic peptides getting 3D structural information for
the intracellular loops of bRH before its crystal structure
was available [52].
However, the synthetic peptide studies, giving only frac-
tional information of the interested proteins, have limitedBMC Biochemistry 2005, 6:23 http://www.biomedcentral.com/1471-2091/6/23
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use in detailed structural and functional characterization
of the interested proteins. Our group has recently been
focusing on developing a link between peptide and pro-
tein studies into one system to further enhance our ability
to characterize the structure/function relationship of pro-
teins. Integrated high-resolution NMR techniques with
synthetic peptide and recombinant protein approaches
have led to the development of "computation-guided
constrained peptide synthesis" and "NMR-experiment-
guided mutagenesis" for aiding in the structural and func-
tional characterization of the TP receptor. Interestingly,
protein-modeling using the TP eLP NMR structures of
other prostanoid receptors has become a new exploration.
It is particularly important since it is not likely that crystal
structures will available for any prostanoid receptors in
the near future, and the high resolution NMR structural
determination for the membrane-bound receptor pro-
teins is unlikely to be solved any time soon, and in addi-
tion, the NMR instrumentation necessary for protein
structural determination is not available in many labs.
In general, the location of the ligand recognition site of
the IP receptor is likely similar to the TP receptor because
it is known that all prostanoids have cross-binding activi-
ties to their receptors. In addition, it is also supported by
the fact of that TP eLP2 important to ligand recognition is
highly conserved in IP (Figure 2). The achievement of this
paper in regards to the successful modeling of the eLPs of
the IP receptor using the NMR structures of the TP eLPs
has supported the hypothesis in which NMR structures
can be applied to the modeling of other prostanoid recep-
tors and use them as a working model for the prediction
of ligand recognition sites in general. It is particularly
important to note that the modeling has also been tested
by key residue mutagenesis using the recombinant IP
receptor protein. The remaining work, including further
mapping the residues involved in the ligand recognition
in the eLPs for the IP receptor by mutagenesis analysis, is
currently under progress in our laboratories.
It shall also be noted that in our previous publication
[42], the prediction of the residues, Ala177 and Gln178,
in the eLP2 important to ligand recognition was sup-
ported by our NMR structural studies using synthetic pep-
tide. These two residues are likely not enough to cover the
pocket. In this manuscript the additional residues are pre-
dicted from the modeling studies based on the NMR struc-
tural model of the extracellular loops of the TP receptor.
In combination of the two separated studies, we have
more confidences that the IP eLP2 provided major resi-
dues to form ligand recognition site in the extracellular
domains of the IP receptor. In addition, the model also
provides important clues for the molecular mechanisms
of the interaction between the ligand and the receptor.
Based on the docking model showing in Figure 5, several
interactions including the charge contact (between the
residue Arg173 and the C1 carboxylate of Iloprost), the
hydrophobic contact (between the residues A172/ M174/
Leu177 and the side chain of Iloprost), and the hydrogen
bond contacts (between the residues Q172/Q178 and the
C11-OH/C15-OH of Iloprost) are predicted. Of course,
the predictions are needed to be further tested by muta-
genesis and structural studies.
Finally, identification of the ligand recognition site on the
extracellular domain of the IP receptor has no conflict
with the identified residues important to the ligand bind-
ing in TM domains for GPCRs. As described in previous
studies, we have proposed two stages of ligand binding to
a prostanoid receptor in which ligand is specifically recog-
nized by the key residues in the extracellular domains of
the receptor first, and then deposited into the receptor TM
domains [43]. For instance, the highly conserved Arg resi-
due in the TM VII is important to the ligand binding, but
it is not likely to be important in determination of the lig-
and selectivities for the different prostanoid receptors.
Thus, identification of the new residues determined the
specific ligand recognition in the extracellular domain is
important, and has not controversial with the identified
ligand binding residues in the TM domain.
Conclusion
We have constructed a 3D working model for the human
IP receptor by homology modeling using the crystal struc-
ture of the bovine rhodopsin TM domains and the NMR
peptide structures of the extracellular loops of the TP
receptor. The residues in the eLP2 domain involved in
forming ligand recognition site were proposed. One of the
key residues, Arg173 important to the ligand recognition
was predicted from the model and confirmed by muta-
genesis. The strategy used for the studies is suitable for
modeling and prediction of ligand recognition pockets for
other prostanoid receptors.
Materials and methods
Materials
COS-7 cells were purchased from ATCC (Manassas, VA).
Medium for culturing COS-7 cells was from Invitrogen.
[3H]-iloprost and iloprost were purchased from Amer-
sham Pharmacia Biotech (Piscataway, NJ). DNA polymer-
ase and DpnI endonuclease were obtained from
Stratagene (La Jolla, CA).
Antibody production
HPLC-purified synthetic peptides corresponding to the
three extracellular loops were mixed and coupled to key-
hole-limpet haemocyanin (KLH) using glutaldehyde. The
peptide antibody was produced in Female New Zealand
White rabbits by Research Genetic Inc. The specific pep-
tide antibody was obtained by affinity chromatographyBMC Biochemistry 2005, 6:23 http://www.biomedcentral.com/1471-2091/6/23
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using the appropriate peptide immobilized on CNBr-acti-
vated Sepharose 4B.
X-ray crystal structure of bRH
The recently reported X-ray crystal structure of bRH with a
resolution at 2.6 Å (1L9H) [53] was downloaded from
Protein Data Bank (PDB), and the 3-D structures of the
TM domains were extracted using Insight II software on a
SIG workstation. These structures were used for homology
modeling of the TM domains of the IP and TP receptors.
NMR structures of the synthetic peptides mimicking the 
extracellular domains of TP receptors
We have solved all of the NMR structures of the con-
strained peptides mimicking the three eLPs of human TP
receptor [43]. These are saved in our database. The NMR
structures were converted to PDB format and then used
for the homology modeling of the IP eLP domains using
the Insight II software on a SIG workstation.
NMR structure of iloprost
The 3-D structure of iloprost, the IP receptor agonist, was
solved by high-resolution 2-D NMR spectroscopy [42],
and the conformation was used for directly docking with
the IP receptor.
Molecular modeling and ligand docking
Molecular modeling, dynamic and ligand docking studies
were performed on a Silicon Graphics Octane workstation
using the software packages Insight II and Discover [54].
The package includes the software for sequence align-
ment, secondary structural calculation, hydropath analy-
sis, protein modeling, energy minimization, molecular
dynamics, molecular annealing and others.
Site-directed mutagenesis
A pAcSG-IP wild-type cDNA was first subcloned into
EcoRI/XbaI sites of pcDNA3.1(+) expression vector. The
IP receptor mutants were then constructed using standard
PCR. The procedures included the use of a pcDNA3.1(+)
vector containing a wild-type IP receptor cDNA as a tem-
plate, and two synthetic oligonucleotide primers contain-
ing the desired mutation for the reaction. The primers,
which were complementary to opposite strands of the
template, extended during the temperature cycling of
95°C for 30s, 53°C for 1 min 30s, and 68°C for 13 min
for a total of 25 cycles with an additional extension cycle
of 68°C for 10 min using Pfu DNA polymerase. The
mutant products were treated with DpnI endonuclease to
digest the parental DNA template and confirmed by DNA
sequencing. The plasmids were then prepared using a
Midiprep kit (Qiagen) for transfection into COS-7 cells
for expression.
Expression of the recombinant IP receptor in COS-7 cells
COS-7 cells were cultured at 37°C in a humidified 5%
CO2 atmosphere in high glucose Dulbecco's modified
Eagle's medium containing 10% fetal bovine serum, anti-
biotics and antimycotics. The cells, which were placed on
100-mm dishes at a density of 1.0 × 106 were cultured
overnight and then transfected with 10 µg of purified
cDNA of pcDNA3.1(+)/IP wild-type or each mutant by
the Lipofectamine method [55], as outlined by the manu-
facture's instructions (Invitrogen). Approximately 48
hours after transfection, the cells were harvested for fur-
ther protein purification.
Western blot analysis
The transfected COS-7 cells were scraped from the plates
into ice-cold PBS buffer, pH 7.4, and collected by centrif-
ugation. After washing three times, the pellet was resus-
pended in a small volume of the same buffer. The protein
was separated by 12% polyacrylamide gel electrophoresis
under denaturing conditions and then transferred to a
nitrocellulose membrane. A band recognized by primary
antibodies against the peptides mimicking the human IP
eLPs was visualized with horseradish peroxidase substrate
as previously described [10].
Ligand binding assay
Ligand binding assay for the IP receptor was performed
using the method as described by [40]. Briefly, the cell
membrane (0.1 mg) in binding buffer was incubated with
4 nM [3H]-iloprost (30,000 cpm) in a 0.1 ml reaction vol-
ume at room temperature for 40 min. The reaction was
terminated by the addition of 5 ml of ice-cold washing
buffer (0.025 M Tris-HCl, pH 7.4). The unbound ligand
was then filtered through a Whatman GF/B glass filter
(Whatman) under a vacuum. The radioactivity of the
receptor-bound [3H]-iloprost remaining on the filter was
counted in 10 ml of scintillation cocktail using a Beckman
β Counter.
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